GHRS (GH Research) ROCE %: -27.92% (As of Mar. 2026)


GHRS GH Research PLC GHRS
35 GF Score
Price $26.50
! 2 Warning Signs
View Full Analysis

What is GH Research ROCE %?

GH Research GHRS +4.41% 35 ROCE % is -27.92% as of Mar. 2026. GuruFocus rates GHRS with a GF Score™ of 35/100. The stock has 2 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. GH Research's annualized ROCE % for the quarter that ended in Mar. 2026 was -27.92%.

GH Research  (NAS:GHRS) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

GH Research ROCE % Related Terms

GH Research ROCE % Historical Data

* Premium members only.

The historical data trend for GH Research's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

GH Research ROCE % Chart

GH Research Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial -6.50 -8.52 -15.14 -19.51 -21.00

GH Research Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -17.64 -12.09 -18.84 -19.78 -27.92
GHRS
35GF Score
GH Research PLC GHRS
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

GH Research ROCE % Calculation

GH Research's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=-48.223/( ( (188.273 - 8.953) + (288.23 - 8.38) )/ 2 )
=-48.223/( (179.32+279.85)/ 2 )
=-48.223/229.585
=-21.00 %

GH Research's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=-75.844/( ( (288.23 - 8.38) + (275.267 - 11.815) )/ 2 )
=-75.844/( ( 279.85 + 263.452 )/ 2 )
=-75.844/271.651
=-27.92 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of -27.92% mean?
GH Research (GHRS) has a ROCE % of -27.92% as of Mar. 2026.
Is GH Research's ROCE % too high?
GH Research's current ROCE % is -27.92%. Overall, GH Research has a GF Score™ of 35/100, reflecting its overall financial health beyond just this single metric.
How does GH Research's ROCE % compare to BHVN and NUVB?
GH Research's ROCE % of -27.92% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Biotechnology company?
A good ROCE % depends on the Biotechnology industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. GH Research's current ROCE % is -27.92%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GH Research stock overvalued right now?
GH Research (GHRS) has a current ROCE % of -27.92%. The current ROCE % is -27.92%. GH Research's overall GF Score™ is 35/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For GH Research (GHRS), the current ROCE % is -27.92% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

GH Research Business Description

Other Exchanges 1KA:Germany
Address Dawson Street, Joshua Dawson House, Dublin 2, IRL, D02 RY95
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.
35GF Score

Get the complete analysis for GHRS

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$26.50
Price